Format

Send to

Choose Destination
Am J Kidney Dis. 2016 Oct;68(4):628-632. doi: 10.1053/j.ajkd.2016.04.016. Epub 2016 May 28.

Pemetrexed-Induced Nephrogenic Diabetes Insipidus.

Author information

1
Department of Medicine, Stanford University School of Medicine, Palo Alto, CA. Electronic address: efung@stanford.edu.
2
Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.

Abstract

Pemetrexed is an approved antimetabolite agent, now widely used for treating locally advanced or metastatic nonsquamous non-small cell lung cancer. Although no electrolyte abnormalities are described in the prescribing information for this drug, several case reports have noted nephrogenic diabetes insipidus with associated acute kidney injury. We present a case of nephrogenic diabetes insipidus without severely reduced kidney function and propose a mechanism for the isolated finding. Severe hypernatremia can lead to encephalopathy and osmotic demyelination, and our report highlights the importance of careful monitoring of electrolytes and kidney function in patients with lung cancer receiving pemetrexed.

KEYWORDS:

Nephrogenic diabetes insipidus; adverse drug reaction; drug toxicity; pemetrexed; proton coupled folate transporters

PMID:
27241854
PMCID:
PMC5035572
DOI:
10.1053/j.ajkd.2016.04.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center